Clinical Trial Update: Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 neoadjuvant trial evaluating Aitua, a PD-1/CTLA-4 bispecific, with nab-paclitaxel and carboplatin in advanced high-grade serous ovarian cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• High-grade Serous Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Aitua
• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers | Phase 2 | Status: NOT_YET_RECRUITING